ESR1 and ovarian carcinoma: Mechanisms that may explain the lower responsiveness of ER-positive ovarian cancer than breast cancer to anti-estrogens include differences in 1) the expression of the subtypes of ER, 2) the expression of ER coactivators, and 3) expression patterns of ER isoforms.